OpenLB
Open Library of Bioscience
Advanced Search
Alzheimer disease and associated disorders
2023 Jul-Sep 01;37 (3): 222-228.

Alzheimer's Behavioral and Psychiatric Burden in Saudi Arabia: Validation of the Saudi Version of the Neuropsychiatric Inventory.

Haythum O Tayeb, Nadeem S Butt, Roaa Khallaf, Bassam Yaghmoor, Mohammed A Basheikh, Sultan H Alamri, Abrar O Baduwailan, Faten Alzaben, Haifa K Abdulghaffar, Harold G Koenig
Author Information
  1. Haythum O Tayeb: The Neuroscience Research Unit and the Mind and Brain Studies Initiative, Division of Neurology, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah. ORCID
  2. Nadeem S Butt: The Faculty of Medicine in Rabigh, King Abdulaziz University, Rabigh.
  3. Roaa Khallaf: Department of Neurology, Neuroscience Center, King Fahad Specialist Hospital Dammam.
  4. Bassam Yaghmoor: The Neuroscience Research Unit and the Mind and Brain Studies Initiative, Division of Neurology, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah.
  5. Mohammed A Basheikh: Division of Geriatrics Departments of Internal Medicine.
  6. Sultan H Alamri: Family Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  7. Abrar O Baduwailan: The Neuroscience Research Unit and the Mind and Brain Studies Initiative, Division of Neurology, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah.
  8. Faten Alzaben: Division of Psychiatry Internal Medicine.
  9. Haifa K Abdulghaffar: The Neuroscience Research Unit and the Mind and Brain Studies Initiative, Division of Neurology, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah.
  10. Harold G Koenig: Division of Psychiatry Internal Medicine.
PMID: 37561963 DOI: 10.1097/WAD.0000000000000563

Abstract

BACKGROUND: The burden of behavioral and psychiatric symptoms in dementia (BPSD) has not been characterized in Saudi patients with Alzheimer disease (AD). Moreover, the Saudi version of the Neuropsychiatric Inventory (SNPI) has not been validated.
OBJECTIVES: The purpose of this study was to validate the SNPI and describe frequency and determinants of BPSD in Saudi AD patients.
METHODS: The SNPI and BEHAVE-AD instruments were administered to community-dwelling Saudi AD patients and their caregivers.
RESULTS: The sample size was 192. The first 59 constituted the validation cohort. Cronbach alpha of the SNPI and BEHAVE-AD were 0.91 and 0.79, respectively. There were significant correlations between: (1) the total SNPI and BEHAVE-AD scores ( r =0.84, P <0.001); (2) analogous SNPI and BEHAVE-AD symptom subscores ( P <0.05); (3) SNPI and BEHAVE-AD caregiver distress ( F =22.6, P <0.001). Inter-rater reliability of the SNPI was excellent (kappa=0.74). Ninety percent of patients experienced 4 SNPI symptoms or more. Patients with stroke and prior psychiatric history were most likely to experience BPSDs. The most common symptom was apathy (82%). Caregiver distress was determined by the total NPI score and impulsiveness subscale score.
CONCLUSIONS: The SNPI is valid and reliable for assessing BPSD in Saudi AD patients. Longitudinal studies of BPSDs in Saudi specialized dementia clinics are needed.

References

Wortmann M. P3-382: global dementia policy overview. Alzheimers Dement. 2016;12(7S_Part_2) 0:P995–P996.
Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63–75 . e2.
Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172:460–465.
Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment results from the cardiovascular health study. JAMA. 2002;288:1475–1483.
Cerejeira J, Lagarto L, Mukaetova-Ladinska E. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.
Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–271.
Tayeb HO, Murray ED, Price BH Dickerson B, Atri A. Neuropsychiatric symptoms of dementia. Dementia: Comprehensive Principles and Practices. Oxford University Press; 2014.
Toot S, Swinson T, Devine M, et al. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr. 2017;29:195–208.
Nobis L, Husain M. Apathy in Alzheimer’s disease. Curr Opin Behav Sci. 2018;22:7–13.
Barbe C, Jolly D, Morrone I, et al. Factors associated with quality of life in patients with Alzheimer’s disease. BMC Geriatr. 2018;18:159.
D’Onofrio G, Sancarlo D, Panza F, et al. Neuropsychiatric symptoms and functional status in Alzheimer’s disease and vascular dementia patients. Curr Alzheimer Res. 2012;9:759–771.
Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 suppl 6):10S–16S.
Ismail Z, Emeremni CA, Houck PR, et al. A comparison of the E-BEHAVE-AD, NBRS and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. Am J Geriatr Psychiatry. 2013;21:78–87.
Boada M, Cejudo JC, Tàrraga L, et al. Neuropsychiatric inventory questionnaire (NPI-Q): spanish validation of an abridged form of the Neuropsychiatric Inventory (NPI). Neurol Barc Spain. 2002;17:317–323.
Feghali Y, Fares Y, Abou Abbas L. Assessment of neuropsychiatric symptoms in dementia: validity and reliability of the Lebanese version of the neuropsychiatric inventory questionnaire. Appl Neuropsychol Adult. 2021;28:588–595.
Zepeda MUP, Guerrero JAR, Carrasco OR, et al. P3-038: validation of the neuropsychiatric inventory questionnaire in a group of Mexican patients with dementia. Alzheimers Dement. 2008;4(4S_Part_16):T527–T528.
de Jonghe JFM, Kat MG, Kalisvaart CJ, et al. Neuropsychiatric inventory questionnaire (NPI-Q): a validity study of the Dutch form. Tijdschr Gerontol Geriatr. 2003;34:74–77.
Matsumoto N, Ikeda M, Fukuhara R, et al. Validity and reliability of the Japanese version of the Neuropsychiatric Inventory Caregiver Distress Scale (NPI D) and the Neuropsychiatric Inventory Brief Questionnaire Form (NPI-Q). No To Shinkei. 2006;58:785–790.
Musa G, Henríquez F, Muñoz-Neira C, et al. Utility of the Neuropsychiatric Inventory Questionnaire (NPI-Q) in the assessment of a sample of patients with Alzheimer’s disease in Chile. Dement Neuropsychol. 2017;11:129–136.
Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–239.
Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer’s disease (BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8(suppl 3):301–308; discussion 351-354.
Jack CR, Albert M, Knopman DS, et al. Introduction to revised criteria for the diagnosis of Alzheimer’s disease: national Institute on Aging and the Alzheimer Association Workgroups. Alzheimers Dement J Alzheimers Assoc. 2011;7:257–262.
Leung VP, Lam LC, Chiu HF, et al. Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). Int J Geriatr Psychiatry. 2001;16:789–793.
Choi SH, Na DL, Kwon HM, et al. The Korean version of the neuropsychiatric inventory: a scoring tool for neuropsychiatric disturbance in dementia patients. J Korean Med Sci. 2009;15:609–615.
Davidsdottir SR, Snaedal J, Karlsdottir G, et al. Validation of the icelandic version of the Neuropsychiatric Inventory with Caregiver Distress (NPI-D). Nord J Psychiatry. 2012;66:26–32.
Camozzato AL, Godinho C, Kochhann R, et al. Validity of the Brazilian version of the Neuropsychiatric Inventory Questionnaire (NPI-Q). Arq Neuropsiquiatr. 2015;73:41–45.
Chaaya M, Phung TKT, El Asmar K, et al. Validation of the Arabic Rowland Universal Dementia Assessment Scale (A-RUDAS) in elderly with mild and moderate dementia. Aging Ment Health. 2016;20:880–887.
ePROVIDETM - Online Support for Clinical Outcome Assessments. Accessed November 27, 2022. https://eprovide.mapi-trust.org/instruments/neuropsychiatric-inventory-12-item-version .
Day GS, Scarmeas N, Dubinsky R, et al. Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN Guidelines Subcommittee. Neurology. 2022;98:619–631.
Saari T, Koivisto A, Hintsa T, et al. Psychometric properties of the neuropsychiatric inventory: a review. J Alzheimers Dis. 2022;86:1485–1499.
You SC, Walsh CM, Chiodo LA, et al. Neuropsychiatric symptoms predict functional status in Alzheimer’s disease. J Alzheimers Dis JAD. 2015;48:863–869.
Chen CT, Chang CC, Chang WN, et al. Neuropsychiatric symptoms in Alzheimer’s disease: associations with caregiver burden and treatment outcomes. QJM Int J Med. 2017;110:565–570.
Hallikainen I, Koivisto AM, Välimäki T. The influence of the individual neuropsychiatric symptoms of people with Alzheimer disease on family caregiver distress—a longitudinal ALSOVA study. Int J Geriatr Psychiatry. 2018;33:1207–1212.
Truzzi A, Valente L, Engelhardt E, et al. The association between caregiver distress and individual neuropsychiatric symptoms of dementia. Dement Neuropsychol. 2013;7:286–291.
Tayeb HO, Muayqil TA, Khallaf RA, et al. The future of Alzheimer disease immunotherapies in Saudi Arabia: consensus Statement of the Saudi Chapter of Cognitive and Behavioral Neurology. Neurosciences J. 2023;28:77–84.

MeSH Term

Humans
Alzheimer Disease
Saudi Arabia
Reproducibility of Results
Caregivers
Behavioral Symptoms
Psychiatric Status Rating Scales
Neuropsychological Tests
Journal Article Research Support, Non-U.S. Gov't

Word Cloud

Similar Articles

Cited By